CFA-Level-II

CFA-INSTITUTE CFA-LEVEL-II DUMPS WITH REAL EXAM QUESTIONS

CFA Level II Chartered Financial Analyst · CFA Level II

PDF Only

Last Updated: Nov 17, 2026
715 Total Questions
$79.00

Test Engine Only

Last Updated: Nov 17, 2026
715 Total Questions
$89.00
  • ✓ Instant download after payment
  • ✓ 90 days of access & free updates
  • ✓ Secure checkout via PayPal

24/7 Customer Support

Questions about your CFA-Level-II purchase or download? Our support team is here for you around the clock.

Money Back Guarantee

Prepare with confidence — if you don't pass after studying with our materials, you get a full refund.

Free Product Updates

Get free updates to your CFA-Level-II materials for your full access period, at no extra cost.

About the CFA-Institute CFA-Level-II Exam

Preparing for the CFA-Institute CFA-Level-II (CFA Level II Chartered Financial Analyst) exam takes more than reading through documentation — it takes practicing with material that reflects what you'll actually see on test day. Our CFA-Level-II dumps are built from real exam-pattern questions and answers, reviewed regularly and updated to stay current with CFA-Institute's own changes to the CFA Level II certification.

What Is the CFA-Institute CFA-Level-II Exam?

CFA-Level-II is the credential exam that validates your knowledge and hands-on ability against CFA-Institute's official CFA Level II blueprint. Rather than testing rote memorization, it's designed to confirm that you can apply the concepts, tools, and best practices covered under the CFA Level II certification in realistic, scenario-based situations. Employers and clients treat an active CFA-Level-II certification as independent, vendor-verified proof of skill — not just a line on a resume — which is exactly why candidates invest real study time into passing it on the first attempt rather than treating it as a formality.

Who Should Take the CFA-Level-II Exam?

The CFA-Level-II exam is aimed at professionals who already work with, or are moving into, roles built around CFA-Institute's technology — including engineers, administrators, consultants, and specialists who need to prove their capability to employers, clients, or their own team. If your day-to-day work involves recommending, implementing, supporting, or troubleshooting solutions that fall under the CFA Level II certification, CFA-Level-II is the exam that turns that practical experience into a recognized, portable credential. Many candidates also pursue it specifically to unlock new job opportunities, qualify for a promotion, or meet a certification requirement set by their employer or a client contract.

Why the CFA Level II Certification Matters

Certifications tied to major technology vendors like CFA-Institute carry weight precisely because they're standardized and independently administered — a hiring manager or client can trust that everyone holding the CFA Level II credential has been tested against the same bar. Passing CFA-Level-II signals that you can be handed real responsibility without needing to be walked through the basics, which is a meaningful differentiator in a competitive job market. It's common for certified professionals to report that the credential strengthened their position in salary negotiations, job interviews, or bids for new client work, simply because it replaces a self-reported claim of skill with a verified one.

How to Prepare Effectively for CFA-Level-II

Because CFA-Level-II is scenario-driven rather than purely fact-based, the most effective preparation combines structured study of the official CFA Level II exam objectives with realistic, repeated practice under exam-like conditions. A few habits consistently separate candidates who pass on their first attempt from those who don't:

  • Work through the full set of official CFA Level II exam objectives methodically, rather than skipping straight to practice questions.
  • Practice with material that mirrors the real CFA-Level-II question style and difficulty, not generic trivia unrelated to how the exam is actually written.
  • Review the reasoning behind every answer — right or wrong — so you understand the underlying principle being tested, not just which letter to pick.
  • Take full timed practice runs close to your test date to build stamina and get comfortable with the pacing you'll need on exam day.
  • Revisit your weaker topic areas repeatedly instead of only reviewing the material you already feel confident about.

Why Choose Tips2Pass CFA-Level-II Dumps

Our CFA-Level-II preparation material is built specifically around the CFA Level II exam blueprint, so your study time goes toward content that actually reflects what you'll face on test day rather than generic study notes. Every purchase gives you the choice of a downloadable PDF for offline review, our interactive practice test engine for exam-day simulation, or both formats bundled together. Questions are reviewed and refreshed on an ongoing basis to stay aligned with CFA-Institute's own changes to the CFA Level II certification, and every purchase includes free updates for your full access period — so the material you're studying from doesn't go stale between now and your test date. If you don't pass after preparing with our materials, our money-back guarantee means your investment is protected.

Common Mistakes Candidates Make on CFA-Level-II

Even well-prepared candidates lose points on exams like CFA-Level-II for a handful of predictable, avoidable reasons. The most common is memorizing isolated facts without understanding when and why to apply them — being able to recite a definition isn't the same as recognizing which concept fits a specific scenario described in a question. Another frequent mistake is rushing: candidates who skim a question's wording miss qualifying details ("choose two," "most cost-effective," "with the least operational overhead") that completely change which answer is correct, even when every option looks technically valid on the surface. Poor time management is another common trap — spending too long on early questions can leave you rushing through the final stretch of the exam. Practicing under realistic timed conditions before your actual test date is one of the simplest ways to avoid all three of these mistakes.

What Happens After You Pass CFA-Level-II

Earning your CFA Level II certification through the CFA-Level-II exam typically opens doors well beyond a single job title — it's evidence you can point to in interviews, performance reviews, and client conversations alike. Many professionals use an associate or foundational-level certification like this one as a stepping stone toward more advanced credentials in the same certification track, building on the same core knowledge to take on more senior or specialized roles over time. For others, it's simply the fastest, most credible way to prove to an employer or client that their skills are current and independently verified, rather than self-described.

Final Thoughts

The CFA-Institute CFA-Level-II exam remains one of the most practical ways to turn real, hands-on experience into a recognized, resume-ready credential. Passing it on your first attempt comes down to studying the right material, in the right way, and practicing under conditions that resemble the real test. Combine focused review of the official CFA Level II exam objectives with our CFA-Level-II dumps and practice questions, and you'll walk into your test appointment fully prepared to earn your certification.

Sample CFA-Level-II Questions

Question # 1
Ivan Johnson is reviewing the investment merits of BioTLab, a fast-growing biotechnology company.
BioTLab has developed several drugs, which arc being licensed to major drug companies. BioTLab
also has several drugs in phase III trials (phase III trials are the last testing stage before FDA
approval). Johnson notes that two drugs recently received approval which should provide BioTLab
solid revenue growth and generate predictable cash flow well into the future. Based on the potential
for the two drugs, BioTLab's estimated annual cash flow growth rate for the next two years is 25%,
and long-term growth is expected to be 12%. Because of BioTLab's attractive investment
opportunities, the company does not pay a dividend. BioTLab's current weighted average cost of
capital is 15% and its stock is currently trading at $50 per share. Financial information for BioTLab for
the most recent 12 months is provided below:
• Net working capita! excluding cash increased from $7,460,000 to $9,985,000;
• Book value increased from $81,250,000 to $101,250,000.
• BioTLab currently has no debt.
• Research facilities and production equipment were purchased for $8,450,000.

• BioTLab held non-operating assets in the amount of $875,000.
• Net income for the 12 months was $20,000,000.
• BioTLab has a marginal tax rate of 40%.
• Noncash charges for depreciation and restructuring for the 12 months were $1,250,000.
BioTLab's management has indicated an interest in establishing a dividend and will fund new drug
research by issuing additional debt.
Johnson also reviews a competitor to BioTLab, Groh Group, which has a larger segment operating in
a highly cyclical business. The Groh Group has a debt to equity ratio of 1.0 and pays no dividends. In
addition, Groh Group plans to issue bonds in the coming year.
Which of the following statements regarding free cash flow models is least likely correct?
  • A. Sensitivity analysis indicates that the FCFE model's valuation of BioTLab's common stock is most sensitive to the company's growth rate.
  • B. FCFE is net income plus depreciation minus net capital expenditures minus the increase in working capital plus net new debt financing.  
  • C. FCFF can be inflated by increasing capital expenditures relative to depreciation. 
Question # 2
Ivan Johnson is reviewing the investment merits of BioTLab, a fast-growing biotechnology company.
BioTLab has developed several drugs, which arc being licensed to major drug companies. BioTLab
also has several drugs in phase III trials (phase III trials are the last testing stage before FDA
approval). Johnson notes that two drugs recently received approval which should provide BioTLab
solid revenue growth and generate predictable cash flow well into the future. Based on the potential
for the two drugs, BioTLab's estimated annual cash flow growth rate for the next two years is 25%,
and long-term growth is expected to be 12%. Because of BioTLab's attractive investment
opportunities, the company does not pay a dividend. BioTLab's current weighted average cost of
capital is 15% and its stock is currently trading at $50 per share. Financial information for BioTLab for
the most recent 12 months is provided below:
• Net working capita! excluding cash increased from $7,460,000 to $9,985,000;
• Book value increased from $81,250,000 to $101,250,000.
• BioTLab currently has no debt.
• Research facilities and production equipment were purchased for $8,450,000.
• BioTLab held non-operating assets in the amount of $875,000.
• Net income for the 12 months was $20,000,000.
• BioTLab has a marginal tax rate of 40%.
• Noncash charges for depreciation and restructuring for the 12 months were $1,250,000.
BioTLab's management has indicated an interest in establishing a dividend and will fund new drug
research by issuing additional debt.
Johnson also reviews a competitor to BioTLab, Groh Group, which has a larger segment operating in
a highly cyclical business. The Groh Group has a debt to equity ratio of 1.0 and pays no dividends. In
addition, Groh Group plans to issue bonds in the coming year.
Which model would be most appropriate in valuing the Groh Group?

  • A. FCFF model. 
  • B. FCFE model. 
  • C. Dividend Discount model. 
Question # 3
Ivan Johnson is reviewing the investment merits of BioTLab, a fast-growing biotechnology company.
BioTLab has developed several drugs, which arc being licensed to major drug companies. BioTLab
also has several drugs in phase III trials (phase III trials are the last testing stage before FDA
approval). Johnson notes that two drugs recently received approval which should provide BioTLab
solid revenue growth and generate predictable cash flow well into the future. Based on the potential
for the two drugs, BioTLab's estimated annual cash flow growth rate for the next two years is 25%,
and long-term growth is expected to be 12%. Because of BioTLab's attractive investment
opportunities, the company does not pay a dividend. BioTLab's current weighted average cost of
capital is 15% and its stock is currently trading at $50 per share. Financial information for BioTLab for
the most recent 12 months is provided below:
• Net working capita! excluding cash increased from $7,460,000 to $9,985,000;
• Book value increased from $81,250,000 to $101,250,000.
• BioTLab currently has no debt.
• Research facilities and production equipment were purchased for $8,450,000.
• BioTLab held non-operating assets in the amount of $875,000.
• Net income for the 12 months was $20,000,000.
BioTLab has a marginal tax rate of 40%.
• Noncash charges for depreciation and restructuring for the 12 months were $1,250,000.
BioTLab's management has indicated an interest in establishing a dividend and will fund new drug
research by issuing additional debt.
Johnson also reviews a competitor to BioTLab, Groh Group, which has a larger segment operating in
a highly cyclical business. The Groh Group has a debt to equity ratio of 1.0 and pays no dividends. In
addition, Groh Group plans to issue bonds in the coming year.
If BioTLabs establishes a dividend and issues additional debt, the most likely effect on FCFF will be;
  • A. no effect. 
  • B. a decrease in FCFF. 
  • C. an increase in FCFF. 
Question # 4
Ivan Johnson is reviewing the investment merits of BioTLab, a fast-growing biotechnology company.
BioTLab has developed several drugs, which arc being licensed to major drug companies. BioTLab
also has several drugs in phase III trials (phase III trials are the last testing stage before FDA
approval). Johnson notes that two drugs recently received approval which should provide BioTLab
solid revenue growth and generate predictable cash flow well into the future. Based on the potential
for the two drugs, BioTLab's estimated annual cash flow growth rate for the next two years is 25%,
and long-term growth is expected to be 12%. Because of BioTLab's attractive investment
opportunities, the company does not pay a dividend. BioTLab's current weighted average cost of
capital is 15% and its stock is currently trading at $50 per share. Financial information for BioTLab for
the most recent 12 months is provided below:
• Net working capita! excluding cash increased from $7,460,000 to $9,985,000;
• Book value increased from $81,250,000 to $101,250,000.
• BioTLab currently has no debt.
• Research facilities and production equipment were purchased for $8,450,000.
• BioTLab held non-operating assets in the amount of $875,000.
• Net income for the 12 months was $20,000,000.
• BioTLab has a marginal tax rate of 40%.
• Noncash charges for depreciation and restructuring for the 12 months were $1,250,000.
BioTLab's management has indicated an interest in establishing a dividend and will fund new drug
research by issuing additional debt.
Johnson also reviews a competitor to BioTLab, Groh Group, which has a larger segment operating in
a highly cyclical business. The Groh Group has a debt to equity ratio of 1.0 and pays no dividends. In
addition, Groh Group plans to issue bonds in the coming year.
Using a two-stage, free cash flow to the firm model, determine which of the following is closest to
the value of BioTLab.
  • A. $419 million. 
  • B. $436 million. 
  • C. $477 million. 
Question # 5
Ivan Johnson is reviewing the investment merits of BioTLab, a fast-growing biotechnology company.
BioTLab has developed several drugs, which arc being licensed to major drug companies. BioTLab
also has several drugs in phase III trials (phase III trials are the last testing stage before FDA
approval). Johnson notes that two drugs recently received approval which should provide BioTLab
solid revenue growth and generate predictable cash flow well into the future. Based on the potential
for the two drugs, BioTLab's estimated annual cash flow growth rate for the next two years is 25%,
and long-term growth is expected to be 12%. Because of BioTLab's attractive investment
opportunities, the company does not pay a dividend. BioTLab's current weighted average cost of
capital is 15% and its stock is currently trading at $50 per share. Financial information for BioTLab for
the most recent 12 months is provided below:
• Net working capita! excluding cash increased from $7,460,000 to $9,985,000;
• Book value increased from $81,250,000 to $101,250,000.
• BioTLab currently has no debt.
• Research facilities and production equipment were purchased for $8,450,000.
• BioTLab held non-operating assets in the amount of $875,000.
• Net income for the 12 months was $20,000,000.
• BioTLab has a marginal tax rate of 40%.
• Noncash charges for depreciation and restructuring for the 12 months were $1,250,000.
BioTLab's management has indicated an interest in establishing a dividend and will fund new drug
research by issuing additional debt.
Johnson also reviews a competitor to BioTLab, Groh Group, which has a larger segment operating in
a highly cyclical business. The Groh Group has a debt to equity ratio of 1.0 and pays no dividends. In
addition, Groh Group plans to issue bonds in the coming year.
Johnson prefers to use free cash flow analysis to value investments. Which of the statements below
is least accurate in describing the advantages of free cash flow valuation models?
  • A. Accounting issues limit the usefulness of reported earnings, while free cash flow is adjusted for these issues.
  • B. Determining free cash flow is easier than dividends. 
  • C. A company must generate free cash flow to grow in the long run. 
Question # 6
Richard Grass is the healthcare analyst for Furrnon Investments and is reviewing the investment
merits of the developing hospice industry. The hospice industry has a short history in the public
market, as several companies have recently completed their initial public offering. Hospice services
are provided to patients diagnosed with terminal illness as an alternative to aggressive medical
management. The use of hospice services at skilled nursing facilities and assisted-living facilities is
forecasted to continue its recent growth. Medicare is the primary payer for hospice services,
accounting for 85% of the approximately $7 billion in industry's revenues. Hospice providers offer
symptom and pain management to patients diagnosed with a terminal illness by their physician. The
program was added to the Medicare benefit package in the early 1980s. Growth in the sector has
only recently. accelerated due to the emergence of a number of for-profit companies. The caregiver
provides a plan for each admitted patient and care is given in any number of healthcare
environments, including the patient's home.
Grass's analysis of the hospice industry has uncovered several facts that are outlined below:
• The industry's revenue annual growth rate has increased from 14% in the late 1990s to 25% in
2008.
• The average length of stay at facilities for hospice patients is increasing.
• Labor costs account for 75% of total expenses, drugs 15% of total expenses, and medical supplies
10%.
• More than 80% of hospice patients are above 65 years old and 30% are above 85 years old.
• Based on the U.S. Census Bureau's statistics, over the next six years (2009-2015), the number of
people in the 65 and older age group will increase annually by 1.4%.
• The Medicare hospice benefit is still underutilized by the terminally ill population, according to
MedPac (an independent advisory committee for the U.S. Congress on healthcare issues).
• Only 30% of Medicare beneficiaries enroll in the hospice benefit before they die.
• In recent years, the U.S. government has approved rate increases for the sector compared to flat or
declining rate trends for other healthcare services.
• The Medicare hospice program has a beneficiary cap which cannot exceed approximately $18,000
annually per person.
• The top six for-profit providers account for about half of the segment's sales.
• The overall hospice provider market is roughly divided into 55% non-profit, 10% U.S. government,
and 35% for-profit.
Grass's analysis has narrowed his search to Hope Company. Hope controls about 7% of the total
hospice service market or 20% of the for-profit market. The company has the only regulator
approved for-profit certificate for the state of Florida, one of the most attractive markets in the
United States. In addition to a strong market share in Florida, Hope has a strong presence in urban
markets like Dallas and San Francisco. Hope has a more diversified revenue base than other publicly
traded for-profit providers.
Grass is forecasting Hope Company's revenues and profits for the next year. Which of the following
statements is least likely a risk Grass should consider in developing his forecast? Furmon
Investment's economist is forecasting a:
  • A. reduction in Medicare's benefit package. 
  • B. recession for the U.S. economy. 
  • C. larger than expected increase for healthcare labor expenditures. 
Question # 7
Richard Grass is the healthcare analyst for Furrnon Investments and is reviewing the investment
merits of the developing hospice industry. The hospice industry has a short history in the public market, as several companies have recently completed their initial public offering. Hospice services
are provided to patients diagnosed with terminal illness as an alternative to aggressive medical
management. The use of hospice services at skilled nursing facilities and assisted-living facilities is
forecasted to continue its recent growth. Medicare is the primary payer for hospice services,
accounting for 85% of the approximately $7 billion in industry's revenues. Hospice providers offer
symptom and pain management to patients diagnosed with a terminal illness by their physician. The
program was added to the Medicare benefit package in the early 1980s. Growth in the sector has
only recently. accelerated due to the emergence of a number of for-profit companies. The caregiver
provides a plan for each admitted patient and care is given in any number of healthcare
environments, including the patient's home.
Grass's analysis of the hospice industry has uncovered several facts that are outlined below:
• The industry's revenue annual growth rate has increased from 14% in the late 1990s to 25% in
2008.
• The average length of stay at facilities for hospice patients is increasing.
• Labor costs account for 75% of total expenses, drugs 15% of total expenses, and medical supplies
10%.
• More than 80% of hospice patients are above 65 years old and 30% are above 85 years old.
• Based on the U.S. Census Bureau's statistics, over the next six years (2009-2015), the number of
people in the 65 and older age group will increase annually by 1.4%.
• The Medicare hospice benefit is still underutilized by the terminally ill population, according to
MedPac (an independent advisory committee for the U.S. Congress on healthcare issues).
• Only 30% of Medicare beneficiaries enroll in the hospice benefit before they die.
• In recent years, the U.S. government has approved rate increases for the sector compared to flat or
declining rate trends for other healthcare services.
• The Medicare hospice program has a beneficiary cap which cannot exceed approximately $18,000
annually per person.
• The top six for-profit providers account for about half of the segment's sales.
• The overall hospice provider market is roughly divided into 55% non-profit, 10% U.S. government,
and 35% for-profit.
Grass's analysis has narrowed his search to Hope Company. Hope controls about 7% of the total
hospice service market or 20% of the for-profit market. The company has the only regulator
approved for-profit certificate for the state of Florida, one of the most attractive markets in the
United States. In addition to a strong market share in Florida, Hope has a strong presence in urban
markets like Dallas and San Francisco. Hope has a more diversified revenue base than other publicly
traded for-profit providers.
Grass is reviewing Hope Company's pricing policy. Which of the following factors is least likely to
contribute to the company's pricing policy?
  • A. Hope Company relies on many different medical suppliers. 
  • B. Hope Company provides a unique service for its customer. 
  • C. Competitors are having difficulty entering many of Hope's key markets. 
Question # 8
Richard Grass is the healthcare analyst for Furrnon Investments and is reviewing the investment
merits of the developing hospice industry. The hospice industry has a short history in the public
market, as several companies have recently completed their initial public offering. Hospice services
are provided to patients diagnosed with terminal illness as an alternative to aggressive medical
management. The use of hospice services at skilled nursing facilities and assisted-living facilities is
forecasted to continue its recent growth. Medicare is the primary payer for hospice services,
accounting for 85% of the approximately $7 billion in industry's revenues. Hospice providers offer
symptom and pain management to patients diagnosed with a terminal illness by their physician. The
program was added to the Medicare benefit package in the early 1980s. Growth in the sector has
only recently. accelerated due to the emergence of a number of for-profit companies. The caregiver provides a plan for each admitted patient and care is given in any number of healthcare
environments, including the patient's home.
Grass's analysis of the hospice industry has uncovered several facts that are outlined below:
• The industry's revenue annual growth rate has increased from 14% in the late 1990s to 25% in
2008.
• The average length of stay at facilities for hospice patients is increasing.
• Labor costs account for 75% of total expenses, drugs 15% of total expenses, and medical supplies
10%.
• More than 80% of hospice patients are above 65 years old and 30% are above 85 years old.
• Based on the U.S. Census Bureau's statistics, over the next six years (2009-2015), the number of
people in the 65 and older age group will increase annually by 1.4%.
• The Medicare hospice benefit is still underutilized by the terminally ill population, according to
MedPac (an independent advisory committee for the U.S. Congress on healthcare issues).
• Only 30% of Medicare beneficiaries enroll in the hospice benefit before they die.
• In recent years, the U.S. government has approved rate increases for the sector compared to flat or
declining rate trends for other healthcare services.
• The Medicare hospice program has a beneficiary cap which cannot exceed approximately $18,000
annually per person.
• The top six for-profit providers account for about half of the segment's sales.
• The overall hospice provider market is roughly divided into 55% non-profit, 10% U.S. government,
and 35% for-profit.
Grass's analysis has narrowed his search to Hope Company. Hope controls about 7% of the total
hospice service market or 20% of the for-profit market. The company has the only regulator
approved for-profit certificate for the state of Florida, one of the most attractive markets in the
United States. In addition to a strong market share in Florida, Hope has a strong presence in urban
markets like Dallas and San Francisco. Hope has a more diversified revenue base than other publicly
traded for-profit providers.
Grass's research report on Hope Company is positive on its investment merits. Grass's report states,
"Hope is uniquely positioned in the hospice industry" Which of the following best supports his
comment?

  • A. Hope Company's strong presence in the Florida market. 
  • B. Hope Company relies on the Medicare program for a majority of its revenues. 
  • C. Hope Company's diversified revenue base has allowed the company to expand beyond the hospice sector.
Question # 9
Richard Grass is the healthcare analyst for Furrnon Investments and is reviewing the investment
merits of the developing hospice industry. The hospice industry has a short history in the public
market, as several companies have recently completed their initial public offering. Hospice services
are provided to patients diagnosed with terminal illness as an alternative to aggressive medical
management. The use of hospice services at skilled nursing facilities and assisted-living facilities is
forecasted to continue its recent growth. Medicare is the primary payer for hospice services,
accounting for 85% of the approximately $7 billion in industry's revenues. Hospice providers offer
symptom and pain management to patients diagnosed with a terminal illness by their physician. The
program was added to the Medicare benefit package in the early 1980s. Growth in the sector has
only recently. accelerated due to the emergence of a number of for-profit companies. The caregiver
provides a plan for each admitted patient and care is given in any number of healthcare
environments, including the patient's home.
Grass's analysis of the hospice industry has uncovered several facts that are outlined below:
• The industry's revenue annual growth rate has increased from 14% in the late 1990s to 25% in
2008.
• The average length of stay at facilities for hospice patients is increasing.
• Labor costs account for 75% of total expenses, drugs 15% of total expenses, and medical supplies
10%.
• More than 80% of hospice patients are above 65 years old and 30% are above 85 years old.
• Based on the U.S. Census Bureau's statistics, over the next six years (2009-2015), the number of
people in the 65 and older age group will increase annually by 1.4%.
• The Medicare hospice benefit is still underutilized by the terminally ill population, according to
MedPac (an independent advisory committee for the U.S. Congress on healthcare issues).
• Only 30% of Medicare beneficiaries enroll in the hospice benefit before they die.
• In recent years, the U.S. government has approved rate increases for the sector compared to flat or
declining rate trends for other healthcare services.
• The Medicare hospice program has a beneficiary cap which cannot exceed approximately $18,000
• More than 80% of hospice patients are above 65 years old and 30% are above 85 years old.
• Based on the U.S. Census Bureau's statistics, over the next six years (2009-2015), the number of
people in the 65 and older age group will increase annually by 1.4%.
• The Medicare hospice benefit is still underutilized by the terminally ill population, according to
MedPac (an independent advisory committee for the U.S. Congress on healthcare issues).
• Only 30% of Medicare beneficiaries enroll in the hospice benefit before they die.
• In recent years, the U.S. government has approved rate increases for the sector compared to flat or
declining rate trends for other healthcare services.
• The Medicare hospice program has a beneficiary cap which cannot exceed approximately $18,000
annually per person.
• The top six for-profit providers account for about half of the segment's sales.
• The overall hospice provider market is roughly divided into 55% non-profit, 10% U.S. government,
and 35% for-profit.
Grass's analysis has narrowed his search to Hope Company. Hope controls about 7% of the total
hospice service market or 20% of the for-profit market. The company has the only regulator
approved for-profit certificate for the state of Florida, one of the most attractive markets in the
United States. In addition to a strong market share in Florida, Hope has a strong presence in urban
markets like Dallas and San Francisco. Hope has a more diversified revenue base than other publicly
traded for-profit providers.
The market share of the top six for-profit providers, together with the presence of non-profit and
government providers, most likely indicates that the:
  • A. threat of new entrants is low in the hospice industry. 
  • B. power of suppliers is low in the hospice industry. 
  • C. threat of substitutes is high in the hospice industry. 
Question # 10
Richard Grass is the healthcare analyst for Furrnon Investments and is reviewing the investment
merits of the developing hospice industry. The hospice industry has a short history in the public
market, as several companies have recently completed their initial public offering. Hospice services
are provided to patients diagnosed with terminal illness as an alternative to aggressive medical
management. The use of hospice services at skilled nursing facilities and assisted-living facilities is
forecasted to continue its recent growth. Medicare is the primary payer for hospice services,
accounting for 85% of the approximately $7 billion in industry's revenues. Hospice providers offer
symptom and pain management to patients diagnosed with a terminal illness by their physician. The
program was added to the Medicare benefit package in the early 1980s. Growth in the sector has
only recently. accelerated due to the emergence of a number of for-profit companies. The caregiver
provides a plan for each admitted patient and care is given in any number of healthcare
environments, including the patient's home.
Grass's analysis of the hospice industry has uncovered several facts that are outlined below:
• The industry's revenue annual growth rate has increased from 14% in the late 1990s to 25% in
2008.
• The average length of stay at facilities for hospice patients is increasing.
• Labor costs account for 75% of total expenses, drugs 15% of total expenses, and medical supplies
10%.
• More than 80% of hospice patients are above 65 years old and 30% are above 85 years old.
• Based on the U.S. Census Bureau's statistics, over the next six years (2009-2015), the number of
people in the 65 and older age group will increase annually by 1.4%.
• The Medicare hospice benefit is still underutilized by the terminally ill population, according to
MedPac (an independent advisory committee for the U.S. Congress on healthcare issues).
• Only 30% of Medicare beneficiaries enroll in the hospice benefit before they die.
• In recent years, the U.S. government has approved rate increases for the sector compared to flat or
declining rate trends for other healthcare services.
• The Medicare hospice program has a beneficiary cap which cannot exceed approximately $18,000
annually per person.
• The top six for-profit providers account for about half of the segment's sales.
• The overall hospice provider market is roughly divided into 55% non-profit, 10% U.S. government,
and 35% for-profit.
Grass's analysis has narrowed his search to Hope Company. Hope controls about 7% of the total
hospice service market or 20% of the for-profit market. The company has the only regulator

approved for-profit certificate for the state of Florida, one of the most attractive markets in the
United States. In addition to a strong market share in Florida, Hope has a strong presence in urban
markets like Dallas and San Francisco. Hope has a more diversified revenue base than other publicly
traded for-profit providers.
Grass is a firm believer in the industry life cycle. Which of the following statements is most accurate
regarding the hospice industry's position in the industry life cycle? The hospice industry is in the:
  • A. growth stage, as indicated by recent growth in sales. 
  • B. pioneer stage, as indicated by recent growth in sales and labor costs. 
  • C. mature stage, as indicated by high labor costs and slow growth in the number of people aged 65 and older

Candidate reviews (0)

No reviews yet for this exam — be the first to leave one.

Leave a review

Reviews are checked before they go live.